home / stock / enta / enta news

ENTA News and Press, Enanta Pharmaceuticals Inc. From 04/30/24

Stock Information
Company Name: Enanta Pharmaceuticals Inc.
Stock Symbol: ENTA
Market: NASDAQ
Website: enanta.com
Menu
ENTA ENTA Quote ENTA Short ENTA News ENTA Articles ENTA Message Board
Get ENTA Alerts

News, Short Squeeze, Breakout and More Instantly...
ENTA - Enanta Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today announced that effective April 29, 2024, the Compensation Committee of Enanta Pharmaceuticals’ Board of Directors g...
ENTA - Enanta Pharmaceuticals to Host Conference Call on May 6 at 4:30 p.m. ET to Discuss its Financial Results for its Fiscal Second Quarter Ended March 31, 2024

Enanta Pharmaceuticals, Inc . (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today announced that it plans to report its financial results for its fiscal second quarter ended March 31, 2024, after the U....

ENTA - (ENTA) Trading Advice

2024-04-21 03:44:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

ENTA - Enanta Pharmaceuticals Announces Data Presentation at ESCMID Global 2024

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for indications in virology and immunology, today announced that data from the company’s SPRINT ( S ARS-Cov-2 PR otease IN hibitor T reatment) stu...
ENTA - (ENTA) Proactive Strategies

2024-03-22 05:50:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

ENTA - Inventiva Phase 2 study for MASH drug meets primary endpoint

2024-03-18 17:45:43 ET More on Inventiva Inventiva: Biotech To Consider Despite Short NASH Study Enrollment Pause Inventiva resumes Phase 3 study for NASH drug, stock up 6% Inventiva drops after adverse event in Phase 3 trial for NASH drug Seeking Alphaȁ...

ENTA - Madrigal climbs amid hopes for new NASH drug; B. Riley upgrades

2024-03-15 08:19:55 ET More on Madrigal Pharmaceuticals Madrigal Pharmaceuticals: Perceived Threat From Eli Lilly Is Overblown Madrigal's MASH Dilemma: Eli Lilly Enters The Fray (Rating Downgrade) Madrigal Pharmaceuticals: Eli Lilly's NASH Data Threatens Resmetirom's...
ENTA - Madrigal wins FDA approval for NASH therapy

2024-03-14 15:45:17 ET More on Madrigal Pharmaceuticals Madrigal Pharmaceuticals: Perceived Threat From Eli Lilly Is Overblown Madrigal's MASH Dilemma: Eli Lilly Enters The Fray (Rating Downgrade) Madrigal Pharmaceuticals: Eli Lilly's NASH Data Threatens Resmetirom's...

ENTA - Madrigal and liver drug developers fall ahead of FDA decision on NASH therapy

2024-03-14 10:42:03 ET More on Madrigal Pharma Madrigal Pharmaceuticals: Perceived Threat From Eli Lilly Is Overblown Madrigal's MASH Dilemma: Eli Lilly Enters The Fray (Rating Downgrade) Madrigal Pharmaceuticals: Eli Lilly's NASH Data Threatens Resmetirom's Potentia...

ENTA - Liver drug developers outperform as U.S. awaits first NASH drug

2024-03-13 13:29:04 ET More on Madrigal Pharmaceuticals Madrigal Pharmaceuticals: Perceived Threat From Eli Lilly Is Overblown Madrigal's MASH Dilemma: Eli Lilly Enters The Fray (Rating Downgrade) Madrigal Pharmaceuticals: Eli Lilly's NASH Data Threatens Resmetirom's...
Previous 10 Next 10